This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
Subjects with advanced solid tumors;
At least one measurable lesion;
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
Expected survival > 12 weeks;
Subjects who have received other antitumor therapy within the prescribed time prior to the first dose;
Subjects with a history of other malignancies within the prescribed time prior to the start of study treatment.
At screening, subjects with a history or evidence of high risk cardiovascular disease;
Subjects with persistent or active infection requiring intravenous anti-infective therapy;